Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aeglea Biothera (AGLE)

Aeglea Biothera (AGLE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,627
  • Shares Outstanding, K 4,049
  • Annual Sales, $ 2,330 K
  • Annual Income, $ -83,810 K
  • EBIT $ -216 M
  • EBITDA $ -215 M
  • 60-Month Beta 2.57
  • Price/Sales 19.19
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -55.75
  • Most Recent Earnings $-3.43 on 11/09/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.67
  • Number of Estimates 1
  • High Estimate -0.67
  • Low Estimate -0.67
  • Prior Year -4.50
  • Growth Rate Est. (year over year) +85.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.43 +42.47%
on 11/10/23
12.54 -4.23%
on 10/30/23
+1.35 (+12.66%)
since 10/27/23
3-Month
8.43 +42.47%
on 11/10/23
16.58 -27.56%
on 09/08/23
-1.06 (-8.15%)
since 08/25/23
52-Week
2.66 +351.50%
on 06/21/23
32.75 -63.33%
on 11/28/22
-18.99 (-61.26%)
since 11/25/22

Most Recent Stories

More News
Aeglea: Q3 Earnings Snapshot

Aeglea: Q3 Earnings Snapshot

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics to Participate in Upcoming September Conference

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Reverse Stock Split

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
ARQT : 12.25 (-4.07%)
Aeglea: Q2 Earnings Snapshot

Aeglea: Q2 Earnings Snapshot

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with best-in-class...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Grant of Inducement Awards

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc....

AGLE : 12.01 (+8.79%)
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END

ONCY : 0.8357 (-2.11%)
ONC.TO : 1.20 (-1.64%)
AGLE : 12.01 (+8.79%)
TALS : 27.20 (-0.73%)
POAI : 0.7900 (-0.13%)
MRTX : 58.70 (-0.17%)

Business Summary

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical...

See More

Key Turning Points

3rd Resistance Point 14.32
2nd Resistance Point 13.33
1st Resistance Point 12.67
Last Price 12.01
1st Support Level 11.02
2nd Support Level 10.03
3rd Support Level 9.37

See More

52-Week High 32.75
Fibonacci 61.8% 21.26
Fibonacci 50% 17.70
Fibonacci 38.2% 14.15
Last Price 12.01
52-Week Low 2.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar